Pancreatic cancer belongs to the most malignant gastrointestinal cancers and, in its
advanced stage, remains a deadly disease for nearly all affected patients. Treatment of …

Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world.
Surgery remains the only treatment offering an advantage in terms of overall survival (5-year …

Background At time of diagnosis, less than 10% of patients with pancreatic
adenocarcinomas (PDAC) are considered to be immediately operable (ie resectable) …

Objectives Prognosis of patients with locally advanced pancreatic adenocarcinoma is
extremely poor. They often suffer from cancer-related pain reducing their quality of life. This …

Many patients with pancreas cancer present with locally advanced pancreatic cancer
(LAPC). The principle tools used for diagnosis and staging of LAPC include endoscopic …

Globally, the death rate of pancreatic ductal adenocarcinoma (PDAC) has doubled over 30
years and is likely to further increase, making PDAC a leading cause of cancer-related death …

Purpose: Evaluation of ultrasound-guided high-intensity focused ultrasound (HIFU) used for
the first time in Germany in patients with inoperable pancreatic cancer for reduction of tumor …

Pancreatic adenocarcinoma is one of the most aggressive human malignancies, ranking 4th
among causes for cancer-related death in the Western world including the United States …

FOLFIRINOX (FFX) was introduced to clinical practice in 2010 following publication of the
PRODIGE 4/ACCORD 11 study, which compared this novel regimen to gemcitabine in …

Background Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic
ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents …